Measuring blood-vessel lining damage in organ donors after brain death

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study enrolls patients declared brain dead who are potential organ donors and characterizes endothelial glycocalyx (EG) degradation using biochemical markers and bedside measurements. Samples and clinical data will be collected prior to organ procurement and linked to donor factors and short-term graft function when available. The investigators will describe EG status across donors to identify patterns associated with worse organ quality or transplant outcomes. Findings are intended to inform strategies for organ optimization, particularly for marginal donors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients in critical condition declared as brain dead by clinical examination

Exclusion Criteria:

* N/A

Where it's running

• University Hospital Hradec Kralove
  Hradec Králové, Czechia Recruiting

Study contacts

• Study coordinator: David Astapenko, MD, PhD
• Email: david.astapenko@fnhk.cz
• Phone: +420495833218

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Anesthesia strategies for organ removal from brain-dead donors

  This trial tests whether using a volatile anesthetic (sevoflurane), giving an opioid (sufentanil), or giving no anesthetic during organ removal from brain-dead donors helps keep blood pressure more stable.

  Recruiting Phase 3 University Hospital, Grenoble · Grenoble · NCT07166991

• Delayed infusion of a naïve T cell–depleted hematopoietic graft with memory T cells for solid organ transplant recipients

  This early study will test whether giving a donor-derived stem cell graft that’s depleted of naïve T cells but includes memory T cells can safely help children and adults who receive kidney, lung, or multivisceral transplants tolerate the new organ with less long-term immune-suppressing medicine.

  Recruiting Phase 1 Hospital Universitario La Paz · Madrid, Madrid · NCT06997471

• Inducing immunological tolerance in kidney transplant patients using stem cell infusion

  This study is testing whether giving stem cells from the same donor to kidney transplant patients can help them stop taking their immunosuppressive medications safely.

  Recruiting Phase 1 University of California, Los Angeles · Los Angeles, California · NCT05525507

• Treating BK Virus Infections in Kidney Transplant Recipients

  This study is testing if changing the way we manage immune suppression and giving a special treatment can help kidney transplant patients with BK virus infections feel better and keep their transplants healthy.

  Recruiting at 13 sites Phase 3 The University of Queensland · Canberra, Australian Capital Territory and 12 other locations · NCT05325008

• Investigating tacrolimus metabolism in kidney transplant patients

  This study looks at how kidney transplant patients process a medication called tacrolimus over four years to see if it affects their kidney health and how genetics might play a role.

  Recruiting University Hospital, Grenoble · Grenoble, Auvergne-Rhône-Alpes and 1 other locations · NCT04526431

• Using Everolimus to Treat Kidney Transplant Patients with Unique Rejection Issues

  This study is testing if the drug Everolimus can help kidney transplant patients who have a specific type of rejection that isn't well understood, to see if it improves their kidney function and overall health.

  Recruiting Hospices Civils de Lyon · Lyon · NCT03955172

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.